Last reviewed · How we verify
Enco+bini (enco-bini)
Enco+bini (generic name: enco-bini) is a Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment drug developed by Pfizer Inc.. It is currently in preclinical development.
Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment
Enco+bini, also known as Encorafenib + Binimetinib, is being studied in clinical trials for the treatment of metastatic melanoma, BRAF v600 mutated metastatic melanoma, metastatic colon cancer, and stage III colon cancer. Enco+bini is being compared to other treatments, including the FOLFIRI Protocol and active surveillance, in these clinical trials.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | enco-bini |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment |
| Therapeutic area | Oncology |
| Phase | preclinical |
Mechanism of action
I cannot provide accurate information about how Enco+bini works without the FDA mechanism text and approved indications. Please supply the complete drug information so I can create an accurate, evidence-based explanation. Providing incomplete or fabricated drug information could be clinically harmful.
Approved indications
Pipeline indications
- Metastatic Melanoma — preclinical
Common side effects
Key clinical trials
- A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Se (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enco+bini CI brief — competitive landscape report
- Enco+bini updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Enco+bini
What is Enco+bini?
How does Enco+bini work?
Who makes Enco+bini?
What is the generic name of Enco+bini?
What drug class is Enco+bini in?
What development phase is Enco+bini in?
Related
- Drug class: All Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing